Assetmark Inc. Acquires 28,701 Shares of Gilead Sciences, Inc. $GILD

Assetmark Inc. raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 22.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 156,118 shares of the biopharmaceutical company’s stock after purchasing an additional 28,701 shares during the period. Assetmark Inc.’s holdings in Gilead Sciences were worth $17,329,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. GoalVest Advisory LLC lifted its stake in Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the period. Corundum Trust Company INC bought a new position in Gilead Sciences in the 3rd quarter worth $26,000. Harbor Asset Planning Inc. purchased a new stake in shares of Gilead Sciences in the 2nd quarter worth about $27,000. Putney Financial Group LLC lifted its position in shares of Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares during the period. Finally, Howard Hughes Medical Institute bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at about $30,000. 83.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on GILD shares. Mizuho raised their price objective on shares of Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. HSBC increased their target price on Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research report on Wednesday, December 10th. Needham & Company LLC lifted their price target on Gilead Sciences from $140.00 to $170.00 and gave the company a “buy” rating in a research report on Wednesday. Argus increased their price objective on Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Finally, Rothschild & Co Redburn raised their price objective on Gilead Sciences from $153.00 to $159.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Twenty-three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $152.50.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the transaction, the insider owned 103,221 shares in the company, valued at $12,831,402.51. The trade was a 2.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Kelly A. Kramer sold 2,805 shares of the stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.10, for a total value of $356,515.50. Following the sale, the director directly owned 1,339 shares in the company, valued at $170,186.90. This trade represents a 67.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 319,391 shares of company stock worth $44,141,101. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $154.98 on Friday. The business has a fifty day moving average price of $130.27 and a 200-day moving average price of $122.32. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.68 and a quick ratio of 1.31. The company has a market capitalization of $192.28 billion, a PE ratio of 22.89, a PEG ratio of 1.24 and a beta of 0.36. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. Gilead Sciences’s revenue was up 4.7% compared to the same quarter last year. During the same period last year, the business earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be paid a dividend of $0.82 per share. The ex-dividend date is Friday, March 13th. This represents a $3.28 annualized dividend and a yield of 2.1%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio (DPR) is 46.68%.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported better-than-expected Q4 results and raised FY26 guidance, driving optimism about near-term revenue and EPS trends. Gilead Sciences, Inc. (NASDAQ:GILD) Just Reported And Analysts Have Been Lifting Their Price Targets
• Positive Sentiment: Major analysts lifted price targets and/or maintained Buy/Outperform ratings after the results — Wolfe Research to $170 (outperform), Oppenheimer to $165 (outperform), TD Cowen to $160 (buy), Deutsche Bank to $155 (buy) — signaling analyst conviction and providing upward pressure on the stock. Wolfe Research price target raise
• Positive Sentiment: BofA raised its price target to $162 and reiterated a Buy, reflecting post‑earnings confidence in Gilead’s franchises. BofA raises PT
• Positive Sentiment: Additional buy ratings from large banks — J.P. Morgan and Scotiabank reiterated/issued Buy calls — adding to institutional endorsement after results. J.P. Morgan buy Scotiabank buy
• Positive Sentiment: Pipeline & product catalysts: Yescarta label expansion and continued HIV franchise momentum (Biktarvy, Descovy, Yeztugo) are being highlighted as durable growth drivers and part of the investment case. Yescarta label expansion & dividend growth
• Neutral Sentiment: Analyst commentary and research pieces (Zacks articles) are flagging Gilead as a momentum/value candidate and discussing whether the HIV portfolio can sustain growth — useful context but not immediate catalysts. Zacks momentum Zacks on HIV portfolio
• Neutral Sentiment: Short‑interest reports in the feed show zero shares / NaN changes and a 0.0 days-to-cover — likely a reporting/data artifact rather than a meaningful market signal. (No external link available in the entry.)

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.